The Role of Scleral Lenses in the Management of Eye Disease

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 15 February 2025 | Viewed by 1197

Special Issue Editor


E-Mail Website
Guest Editor
Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Interests: cornea; confocal microscopy; corneal diseases; corneal topography; refractive surgery; glaucoma; optometry and vision science; scleral contact lenses

Special Issue Information

Dear Colleagues,

The popularity and availability of scleral lenses for the treatment of corneal disease have expanded remarkably over the past 20 years. Patients who formerly faced surgery as the only option for corneal disease can now put off the “inevitable” through the improved visual correction of scleral lenses. Other patients who faced vision loss or significant disruption to their quality of life due to an exposed cornea can now regain functional vision and ocular comfort through the use of scleral lenses. Corneas that could no longer tolerate other lens modalities have found renewed hope with scleral lenses. New technologies have also been developed to enhance the fitting of scleral lenses; ocular surface topographers and correction of higher-order aberrations are expanding the possibilities with this lens design. This Special Issue focused on scleral lenses aims to promote a greater understanding of the role scleral lenses can play in eye care and hopes to examine new designs and new research that helps to improve the lens fitting and wearing experience.

Dr. Cherie B. Nau
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • scleral lenses
  • corneal irregularity
  • corneal disease
  • dry eye disease
  • irregular astigmatism
  • keratoconus
  • meibomian gland dysfunction
  • midday fogging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2998 KiB  
Article
Short-Term Efficacy and Safety of Scleral Lenses in the Management of Severe Dry Eye in a Chinese Population
by Chuwei Lu, Danjie Han, Li Zeng, Jiaxu Hong, Daddi Fadel, Xingtao Zhou, Zhi Chen and Qihua Le
J. Clin. Med. 2025, 14(3), 658; https://doi.org/10.3390/jcm14030658 - 21 Jan 2025
Viewed by 950
Abstract
Background: Scleral lenses (SLs) are recommended in DEWS II to treat dry eye (DE) patients that do not respond well to conventional therapies. This study aimed to evaluate the short-term (one month) efficacy and safety of SLs in the management of severe DE. [...] Read more.
Background: Scleral lenses (SLs) are recommended in DEWS II to treat dry eye (DE) patients that do not respond well to conventional therapies. This study aimed to evaluate the short-term (one month) efficacy and safety of SLs in the management of severe DE. Methods: This single-center prospective study enrolled 15 patients (22 eyes) who were diagnosed with severe DE. The Ocular Surface Disease Index (OSDI), the Chinese version of the 25-item National Eye Institute Visual Function Questionnaire (CHI-VFQ-25), and LogMAR best-corrected visual acuity (BCVA) were evaluated at baseline and one month following SL fitting. DE-related parameters were obtained and analyzed before and after one month of SL treatment, including tear-film breakup time (TBUT), corneal fluorescein staining (CFS), non-invasive breakup time (NIBUT), tear meniscus height (TMH), Schirmer I test (SIT), and meibomian gland (MG) dropout. Complications and adverse events were monitored. Results: OSDI scores (53.9 ± 28.1 vs. 10.4 (4.2–25), p = 0.0001) and CFS scores (10.2 ± 3.9 vs. 7 (0–12), p = 0.001) decreased after one month of SL therapy, while CHI-VFQ-25 scores (74.4 (54.8–83.8) vs. 95 (78.7–98), p = 0.0001) and TBUT (0.6 ± 0.5 vs. 2.2 ± 1.0, p < 0.0001) increased significantly. LogMAR BCVA improved from 0 (0–0.1) to 0 (0–0) (p = 0.0147). The average types of medications per eye decreased from 2.82 ± 1.01 to 1.32 ± 0.64 (p = 0.025), and the proportion of eyes using glucocorticoids significantly decreased from 63.6% to 13.6% (p = 0.001). No severe SL-related adverse events were reported. Conclusions: SL treatment quickly alleviated subjective symptoms as well as clinical signs of DE with good safety and enhanced the visual function and vision-related quality of life, showing its usefulness in the management of severe DE. Full article
(This article belongs to the Special Issue The Role of Scleral Lenses in the Management of Eye Disease)
Show Figures

Figure 1

Back to TopTop